An immunohistochemical method that differentiates Cryptococcus neofarmans varieties and serotypes in formalin-fixed paraffin-embedded tissues

Medical Mycology

Volumn 39, Issue 6, 2001, Pages 523-533

  Krockenberger, M B ^a   Canfield, P J ^a   Kozel, T R ^a   Shinoda, T ^a   Ikeda, R ^a   Wigney, D I ^a   Martin, P ^a   Barnes, K ^a   Malik, R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cryptococcosis; Cryptococcus neofarmans; Cryptococcus neoformans var. gattii; Immunohistochemical

Indexed keywords

AGAR; BROMOTHYMOL BLUE; CANAVANINE; FORMALDEHYDE; GLYCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 302; MONOCLONAL ANTIBODY 471; MONOCLONAL ANTIBODY CRND8; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL DISEASE; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BEAR; CAT; CLASSIFICATION; COMPARATIVE STUDY; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; DOG; FERRET; FUNGUS CULTURE; FUNGUS IDENTIFICATION; HISTOLOGY; HOST PARASITE INTERACTION; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; ISOLATION PROCEDURE; MICROBIOLOGICAL EXAMINATION; MICROSCOPY; MYCOLOGY; NONHUMAN; RANDOM AMPLIFIED POLYMORPHIC DNA; RAT; SEROEPIDEMIOLOGY; SEROTYPE; VALIDATION PROCESS; VETERINARY MEDICINE;

ANIMALIA; CANIS FAMILIARIS; CRYPTOCOCCUS BACILLISPORUS; CRYPTOCOCCUS NEOFORMANS VAR. NEOFORMANS; FELIS CATUS; FILOBASIDIELLA NEOFORMANS; FUNGI; MUSTELA PUTORIUS FURO;

EID: 0035662849     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.39.6.523.533     Document Type: Article

References (59)

1. Epidemiologic differences between the two varieties of Cryptococcus neoformans
2. High prevalence of Cryptococcus neoformans var. gattii in tropical and subtropical regions
3. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis
4. Cryptococcosis in the era of AIDS: 100 years after the discovery of Cryptococcus neoformans
5. Veterinary aspects of cryptococcosis. Milan, 1993
6. Taxonomic studies on Filobasidiella species and their anamorphs
7. An atypical strain of Cryptococcus neoformans (San Felice) Vuillemin 1894. II. Cryptococcus neoformans var. gattii var. nov
8. Serologic grouping of Cryptococcus neoformans
9. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columbia livia)
10. Serotypes of Australian environmental and clinical isolates of Cryptococcus neoformans
11. Epidemiologic differences among serotypes of Cryptococcus neoformans
12. Epidemiology of cryptococcosis in France: A 9-year survey (1985-1993). French Cryptococcosis Study Group
13. Cryptococcus neoformans var. grubii: Separate varietal status for Cryptococcus neoformans serotype A isolates
14. Ecology of Cryptococcus neoformans and prevalence of its two varieties in AIDS and non-AIDS associated cryptococcosis
15. Cryptococcus neoformans var. gattii in Australia
16. Cryptococcus neoformans var. gattii
17. Natural habitat of Cryptococcus neoformans var. gattii
18. Ecology, life cycle, and infectious propagule of Cryptococcus neoformans
19. The ecology of Cryptococcus neoformans
20. Environmental isolation of Cryptococcus neoformans var. gattii from Eucalyptus tereticornis
21. Environmental isolation of Cryptococcus neoformans var. gattii from California
22. Presence of alpha and a mating types in environmental and clinical collections of Cryptococcus neoformans var. gattii strains from Australia
23. Isolation of Cryptococcus neoformans var. gattii from Eucalyptus camaldulensis in India
24. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans
25. Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestations and outcome
26. Analysis of leucocytes and lymphocyte subsets in cats with naturally occurring cryptococcosis but differing feline immunodeficiency virus status
27. Serum antibody response to Cryptococcus neoformans in cats, dogs and koalas with and without active infection
28. Mycological findings in feline immunodeficiency virus-infected cats
29. Cryptococcosis in a cat seropositive for feline immunodeficiency virus
30. Cryptococcal infection in cats: Factors influencing treatment outcome, and results of sequential serum antigen titers in 35 cats
31. Clinical and serologic evaluation of cats with cryptococcosis
32. Meningoencephalitis in a koala (Phascolarctus cinereus) due to Cryptococcus neoformans var. gattii infection
33. Cryptococcus neoformans in tropical northern Australia: Predominantly variant gattii with good outcomes
34. Diagnosis, identification and epidemiology of Cryptococcus neoformans infection
35. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C)
36. Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay
37. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection
38. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell
39. The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays
40. Monoclonal antibody-mediated toxicity in Cryptococcus neoformans infection: Mechanism and relationship to antibody isotype
41. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection
42. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies
43. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide
44. Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule
45. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide
46. Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D
47. The roles of histology and immunohistology in the investigation of marsupial disease and normal lymphoid tissue
48. Immunohistological staining of lymphoid tissue in four Australian marsupial species using species cross-reactive antibodies
49. Biochemical serogrouping of clinical isolates of Cryptococcus neoformans
50. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates
51. Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule
52. Serotypes of Cryptococcus neoformans in patients with AIDS
53. A latex cryptococcal antigen agglutination test for diagnosis and monitoring of therapy for cryptococcosis
54. Cryptococcosis in dogs: A retrospective study of 20 consecutive cases
55. Cryptococcosis in cats: Clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole
56. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat
57. Cryptococcus neoformans meningitis in the rat
58. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis